Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing regenerative medicine sector and give international competitors like China a strategic advantage.
\n\n
Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing regenerative medicine sector and give international competitors like China a strategic advantage.
One year after its launch, the Trump Route for International Peace and Prosperity (TRIPP) serves as a strategic land corridor linking Azerbaijan, Armenia, and Turkey to enhance Eurasian security and…
Maybe a wealth tax can be put to good use by our elected officials. Or maybe letting the billionaires keep and invest their money is a better alternative.